BridgeBio Pharma Net Income 2018-2024 | BBIO
BridgeBio Pharma net income from 2018 to 2024. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
BridgeBio Pharma Annual Net Income
(Millions of US $) |
| 2023 |
$-643 |
| 2022 |
$-481 |
| 2021 |
$-563 |
| 2020 |
$-449 |
| 2019 |
$-261 |
| 2018 |
$-131 |
| 2017 |
$-31 |
BridgeBio Pharma Quarterly Net Income
(Millions of US $) |
| 2024-06-30 |
$-73 |
| 2024-03-31 |
$-35 |
| 2023-12-31 |
$-168 |
| 2023-09-30 |
$-177 |
| 2023-06-30 |
$-158 |
| 2023-03-31 |
$-140 |
| 2022-12-31 |
$-138 |
| 2022-09-30 |
$-137 |
| 2022-06-30 |
$-10 |
| 2022-03-31 |
$-196 |
| 2021-12-31 |
$-147 |
| 2021-09-30 |
$-156 |
| 2021-06-30 |
$-96 |
| 2021-03-31 |
$-163 |
| 2020-12-31 |
$-120 |
| 2020-09-30 |
$-116 |
| 2020-06-30 |
$-121 |
| 2020-03-31 |
$-92 |
| 2019-12-31 |
$-73 |
| 2019-09-30 |
$-60 |
| 2019-06-30 |
$-66 |
| 2019-03-31 |
$-61 |
| 2018-12-31 |
|
| 2018-09-30 |
$-31 |
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.791B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
